Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
  • C07D495/14—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• kinase inhibitors such as dasatinib and erlotinib are used in the treatment of cancer, but their adverse effects remains a serious problem.
• Dasatinib increases the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH), while serious gastrointestinal tract, skin, and ocular disorders have been observed in patients taking the erlotinib.
• PAH pulmonary hypertension
• the clinical efficacy of kinase inhibitors is limited by the development of drug resistance. Accordingly, there is a need to identify novel and efficacious therapeutic strategies that mitigate the limitations of current anti-cancer drugs.
• the present invention is based, at least in part, on the unexpected discovery that combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs are particularly effective at treating subjects with neoplasia.
• BET bromodomain and extra-terminal
• the method comprises administering to a subject in need thereof JQl and/or its analog in combination with a kinase inhibitor selected from the group consisting of MK2206, dasatinib, AZD6244, crizotinib, CYT387, Lapatinib, flavopiridol, y-27632, erlotinib, Afatinib, Axitinib, Bosutinib, cetuximab, Fostamatinib, Gefitinib, Imatinib, Lapatinib, Lenvatinib, Mubritinib, Nilotinib, Panitumumab, Pazopanib, Ruxolitinib,
• a kinase inhibitor selected from the group consisting of MK2206, dasatinib, AZD6244, crizotinib, CYT387, Lapatinib, flavopiridol, y-27632,
• the kinase inhibitor is selected from the group consisting of crizotinib, CYT387, Lapatinib, and flavopiridol.
• JQl and/or its analog is administered separately, sequentially or simultaneously with the kinase inhibitor.
• methods of treating neoplasia comprise administering to a subject in need thereof JQl and/or its analog in combination with an anti-apoptotic agent in an amount effective to treat the neoplasia.
• the anti-apoptotic agent is selected from the group consisting of ABT263, ABT199, ABT737, and obatoclax.
• JQl and/or its analog is administered separately, sequentially or simultaneously with the anti-apoptotic agent.
• methods of treating neoplasia comprise administering to a subject in need thereof JQl and/or its analog in combination with an anti-neoplastic agent selected from the group consisting of vincristine, etoposide, 17-AAG, adrucil, velcade, SAHA, doxil, gemcitabine, AZD2281, DBZ, ifosfamide, revlimid, prednisone, rituximab, Bevacizumab, Pegaptanib, and Ranibizumab in an amount effective to treat the neoplasia.
• the anti-neoplastic agent is velcade or gemcitabine.
• JQl and/or its analog is administered separately, sequentially or simultaneously with the anti-neoplastic agent.
• methods of treating neoplasia comprise administering to a subject in need thereof an effective amount of JQl and/or its analog in combination with temsirolimus or BEZ235, wherein temsirolimus or BEZ235 is administered at a dose where it alone has no anti-neoplastic effect.
• JQl and/or its analog is administered separately, sequentially or
• the subject is a mammal. In some embodiments, the subject is a human patient. In some embodiments, the subject has neoplasia selected from the group consisting of selected from the group consisting of lung cancer, lymphomas including diffuse large B-cell lymphoma and Burkitt' s lymphoma, prostate cancer, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain cancer, CNS cancer, breast cancer, cervical cancer, choriocarcinoma, colon cancer, rectum cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, intra-epithelial neoplasm, kidney cancer, larynx cancer, leukemia, liver cancer, lung cancer, hematologic neoplasias, melanoma, myeloma, neuroblastoma, oral cavity cancer, ovarian cancer, pancreatic cancer, retino
• the neoplasia is lung cancer. In some embodiments, the neoplasia is diffuse large B-cell lymphoma. In some embodiments, the neoplasia is Burkitt' s lymphoma.
• the subject is further treated with an additional anti-neoplasia therapy.
• the additional anti-neoplasia therapy is surgery, radiation therapy, chemotherapy, gene therapy, DNA therapy, viral therapy, RNA therapy, adjuvant therapy, immunotherapy or a combination thereof.
• JQl and/or its analog is JQl.
• compositions comprise an effective amount of JQl or an analog thereof, and a kinase inhibitor selected from the group consisting of MK2206, dasatinib, AZD6244, crizotinib, CYT387, Lapatinib, flavopiridol, y-27632, erlotinib, Afatinib, Axitinib, Bosutinib, cetuximab, Fostamatinib, Gefitinib, Imatinib, Lapatinib, Lenvatinib, Mubritinib, Nilotinib, Panitumumab, Pazopanib, Ruxolitinib, Sorafenib, Sunitinib, Trastuzumab, Vandetanib, and Vemurafenib.
• a kinase inhibitor selected from the group consisting of MK2206, dasatinib, AZD6244, crizot
• a kit comprising a package containing a container containing JQl or an analog thereof, and a container containing a kinase inhibitor selected from the group consisting of MK2206, dasatinib, AZD6244, crizotinib, CYT387, Lapatinib, flavopiridol, y-27632, erlotinib, Afatinib, Axitinib, Bosutinib, cetuximab, Fostamatinib, Gefitinib, Imatinib, Lapatinib, Lenvatinib, Mubritinib, Nilotinib,
• Panitumumab, Pazopanib, Ruxolitinib, Sorafenib, Sunitinib, Trastuzumab, Vandetanib, and Vemurafenib is provided.
• Fig. 1 depicts isobolograms demonstrating the synergy between kinase inhibitors and JQ1.
• Points below the 1 to 1 line connecting the X and Y axes are 'synergistic', points near the line are 'additive', and points above it are antagonistic.
• Fig. 2 depicts isobolograms representing the synergy between anti-apoptotic agents and JQ1.
• Fig. 3 depicts isobolograms representing the synergy between anti-neoplastic agents and JQ1.
• Fig. 4 depicts isobolograms representing the additive effects between temsirolimus or
• Fig. 5 shows the dose response curves for single agents.
• the present invention is based, at least in part, on the surprising discovery that combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs are particularly effective at treating subjects with neoplasia.
• BET bromodomain and extra-terminal
• certain chemotherapeutic drugs are particularly effective at treating subjects with neoplasia.
• JQ1 bromodomain inhibitor thieno-triazolo- 1 ,4-diazepine
• certain chemotherapeutics such as specific kinase inhibitors, and anti-apoptotic agents
• JQ1 and/or its analogs with certain kinase inhibitors, anti-apoptotic agents and other specific anti-neoplastic agents is more effective in treating neoplasia than the additive effects of the individual therapeutic agents.
• the synergistic effect of the combination of therapeutic agents described herein permits the use of lower dosages of one or more of the therapeutic agent(s) and/or less frequent administration of the agent(s) to a subject with neoplasia.
• the ability to utilize a lower dosage of one or more therapeutic agent(s) and/or to administer the therapeutic agent(s) less frequently reduces the toxicity associated with the administration of the agent(s) to a subject without reducing the efficacy of the therapy in the treatment of neoplasia.
• the synergistic effect results in improved efficacy of the agents in the prevention, management or treatment of neoplasia.
• the synergistic effect of the combination of therapeutic agents described herein helps to avoid or reduce adverse or unwanted side effects associated with the use of either therapeutic agent alone.
• neoplasia means a disease state of a human or an animal in which there are cells and/or tissues which proliferate abnormally.
• a neoplasm can be benign, potentially malignant (pre-cancer), or malignant (cancer).
• cancers that may be treated with the combinations described herein include, but are not limited to, solid tumors and hematological cancers.
• Solid tumors are exemplified by tumors of the breast, bladder, bone, brain, central and peripheral nervous system, colon, connective tissue, endocrine glands (e.g., thyroid and adrenal cortex), esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, muscle, ovary, pancreas, penis, prostate gland, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina, and vulva.
• inherited cancers exemplified by retinoblastoma and Wilms' tumor.
• primary tumors in said organs are included as well as corresponding secondary tumors in distant organs ("tumor metastases").
• Hematological cancers are exemplified by aggressive and indolent forms of leukemia and lymphoma, namely diffuse large B cell lymphoma, non-Hodgkin's disease, chronic and acute myeloid leukemia (CML/AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease, Burkitt's lymphoma, multiple myeloma, and T-cell lymphoma. Also included are myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, cancers of unknown primary site as well as AIDS-related malignancies.
• CML/AML chronic and acute myeloid leukemia
• ALL acute lymphoblastic leukemia
• CLL chronic lymphocytic leukemia
• Hodgkin's disease Burkitt's lymphoma
• multiple myeloma multiple myeloma
• T-cell lymphoma
• benign neoplasms that may be treated with the combinations described herein include, but are not limited to, benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman disease, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, and juvenile polyposis syndrome.
• the BET (bromodomain and extra-terminal) proteins are four closely related bromodomain-containing proteins (BRD2, BRD3, BRD4, and BRDT) which constitute a subset of the larger family of 47 bromodomain-containing proteins.
• Bromodomains are acetyl-lysine binding pockets that target bromodomain-containing proteins to histones and thereby affect chromatin structure and function.
• the binding of BET protein bromodomains to chromatin regulates gene expression and small molecule inhibition of that binding produces selective effects on gene expression. Small molecule inhibition of BET
• bromodomains leads to selective killing of tumor cells across a broad range of hematologic malignancies and solid tumors.
• BET bromodomain inhibitors known in the art, include JQ1 and its analogs which have been described in US 2013/0184264, the disclosure of which is incorporated herein by reference.
• the methods, pharmaceutical compositions and kits of the present invention comprise the BET bromodomain inhibitors described in US 2013/0184264, and incorporated herein by reference.
• the present invention further encompasses pharmaceutically acceptable salts of such compounds.
• the methods, pharmaceutical compositions and kits of the present invention comprise JQ1 or pharmaceutically acceptable salts thereof.
• kinase refers to a large class of enzymes which catalyze the transfer of the ⁇ -phosphate from ATP to the hydroxyl group on the side chain of Ser/Thr or Tyr in proteins and peptides and are intimately involved in the control of various important cell functions, perhaps most notably: signal transduction, differentiation and proliferation.
• signal transduction, differentiation and proliferation There are estimated to be about 2,000 distinct protein kinases in the human body and although each of these phosphorylate particular protein/peptide substrates, they all bind the same second substrate ATP in a highly conserved pocket.
• About 50% of the known oncogene products are protein tyrosine kinases PTKs and their kinase activity has been shown to lead to cell transformation.
• IQ1 and/or its analog is administered in combination with kinase inhibitors selected from the group consisting of MK2206, dasatinib, AZD6244 (Selumetinib), crizotinib, CYT387, Lapatinib, flavopiridol, y-27632, erlotinib, Afatinib, Axitinib, Bosutinib, cetuximab, Fostamatinib, Gefitinib, Imatinib, Lapatinib, Lenvatinib, Mubritinib, Nilotinib, Panitumumab, Pazopanib, Ruxolitinib, Sorafenib, Sunitinib,
• kinase inhibitors selected from the group consisting of MK2206, dasatinib, AZD6244 (Selumetinib), crizotinib, CYT387,
• the kinase inhibitor is selected from the group consisting of MK2206, dasatinib, AZD6244 (Selumetinib), crizotinib, CYT387, Lapatinib, and flavopiridol. As shown in the Examples described below, a number of kinase inhibitors including MK2206, dasatinib, AZD6244 (Selumetinib), and crizotinib gave a synergistic response when administered in combination with JQ1.
• kinases activate each other and similar pathways that then terminate in the nucleus where the signal is acted on by transcription factors. Since JQ1 targets BRD4 which is a critical adapter for many transcription factors, in view of the data described herein, a synergistic response is expected when the kinase inhibitors described herein are administered in combination with JQ1.
• JQ1 and/or its analog is administered in combination with an anti-apoptotic agent.
• an anti-apoptotic agent is an agent that inhibits apoptosis. Such an agent can be a small organic or inorganic molecule. It may also be nucleic acid or peptide in nature.
• Non-limiting examples of anti-apoptotic agents include ABT263, ABT199, ABT737, ABT737, and obatoclax.
• JQ1 and/or its analog is administered in combination with an anti-neoplastic agent selected from the group consisting of vincristine, etoposide, 17-AAG, adrucil, velcade, SAHA, doxil, gemcitabine, AZD2281 (Olaparib), DBZ, ifosfamide, revlimid (lenalidomide), prednisone, rituximab, Bevacizumab, Pegaptanib, and Ranibizumab in an amount effective to treat the neoplasia.
• the anti-neoplastic agent selected from the group consisting of vincristine, etoposide, 17-AAG, adrucil, velcade and gemcitabine.
• JQ1 and/or its analog is administered in combination with temsirolimus or BEZ235, wherein temsirolimus or BEZ235 is administered at a dose where it alone has no anti-neoplastic effect.
• temsirolimus and BEZ235 increased the effect of JQ1 at doses where they alone have no effect.
• the recommended dose of temsirolimus is 25 mg IV infused over 30-60 minutes once per week.
• temsirolimus is administered at a dose of 20mg, 15 mg, 10 mg or 5 mg/week with JQ1, in some embodiments IV infused over 30-60 minutes once per week.
• BEZ235 is administered at a dose of 50 mg; 100 mg; 150 mg; 200 mg; 250 mg; 300 mg; 350 mg; 400 mg; 450 mg; 500 mg; 650 mg; 700 mg; 750 mg; or 800 mg orally once daily with JQ1.
• the term "in combination” refers to the use of more than one therapeutic agent.
• the use of the term “in combination” does not restrict the order in which the therapeutic agents are administered to a subject with neoplasia.
• a first therapeutic agent such as JQ1 or its analog, can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapeutic agent, such as a kinase inhibitor, anti-apopt
• a "subject" to which administration is contemplated includes, but is not limited to, humans; commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs) and birds ⁇ e.g. , commercially relevant birds such as chickens, ducks, geese, and/or turkeys).
• a subject in need of treatment is a subject identified as having neoplasia, i.e., the subject has been diagnosed by a physician ⁇ e.g., using methods well known in the art) as having neoplasia.
• the subject in need of treatment is a subject suspected of having or developing a neoplasia, such as a subject presenting one or more symptoms indicative of a neoplasia.
• the term "subject in need of treatment” further includes people who once had a neoplasia but whose symptoms have ameliorated.
• the one or more symptoms or clinical features of neoplasia depend on the type and location of the tumor. For example, lung tumors may cause coughing, shortness of breath, or chest pain. Tumors of the colon can cause weight loss, diarrhea, constipation, iron deficiency anemia, and blood in the stool.
• administer refers to implanting, absorbing, ingesting, injecting, or inhaling the one or more therapeutic agents.
• treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of neoplasia.
• treatment may be administered after one or more signs or symptoms have developed or have been observed.
• treatment may be administered in the absence of signs or symptoms of the neoplasia.
• treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g. , in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.
• an “effective amount” refers to an amount sufficient to elicit the desired biological response, i.e., treating the neoplasia.
• the effective amount of the compounds described herein may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject.
• An effective amount includes, but is not limited to, that amount necessary to slow, reduce, inhibit, ameliorate or reverse one or more symptoms associated with neoplasia. For example, in the treatment of neoplasia, such terms may refer to a reduction in the size of the tumor.
• An effective amount of a compound may vary from about 0.001 mg/kg to about 1000 mg/kg in one or more dose administrations, for one or several days (depending on the mode of administration). In certain embodiments, the effective amount varies from about 0.001 mg/kg to about 1000 mg/kg, from about 0.01 mg kg to about 750 mg/kg, from about 0.1 mg/kg to about 500 mg/kg, from about 1.0 mg/kg to about 250 mg/kg, and from about 10.0 mg/kg to about 150 mg/kg.
• the subject is further treated with one or more additional anti- neoplasia therapy.
• the subject may undergo surgery, radiation therapy, chemotherapy, gene therapy, DNA therapy, viral therapy, RNA therapy, adjuvant therapy, immunotherapy or a combination thereof.
• the compounds provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol.
• enteral e.g., oral
• parenteral intravenous
• intramuscular intra-arterial
• intramedullary intrathecal
• subcutaneous intraventricular
• transdermal transdermal
• interdermal interdermal
• rectal intravaginal
• topical as by powders, ointments, creams, and/or drops
• mucosal nasal,
• systemic intravenous injection regional administration via blood and/or lymph supply, and/or direct administration to an affected site.
• direct administration to an affected site.
• the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g. , its stability in the environment of the gastrointestinal tract), and/or the condition of the subject (e.g. , whether the subject is able to tolerate oral administration).
• the exact amount of a compound required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound, mode of administration, and the like.
• the desired dosage can be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks.
• the desired dosage can be delivered using multiple administrations (e.g. , two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
• an effective amount of a compound for administration one or more times a day to a 70 kg adult human may comprise about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg, of a compound per unit dosage form.
• the compounds provided herein may be administered at dosage levels sufficient to deliver from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, preferably from about 0.1 mg/kg to about 40 mg kg, preferably from about 0.5 mg kg to about 30 mg/kg, from about 0.01 mg kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, and more preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
• dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult.
• the amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
• compositions described herein can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include the steps of bringing the active ingredients such as JQ1 or an analog thereof into association with a carrier or excipient, and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping, and/or packaging the product into a desired single- or multi-dose unit.
• Pharmaceutical compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
• a "unit dose" is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
• the pharmaceutical preparations of the present invention may include or be diluted into a pharmaceutically-acceptable carrier.
• pharmaceutically-acceptable carrier means one or more compatible fillers, diluents or other such substances, which are suitable for administration to a human or other mammal such as a dog, cat, or horse.
• carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.
• the carriers are capable of being commingled with the preparations of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy or stability.
• Carriers suitable for oral, subcutaneous, intravenous, intramuscular, etc. formulations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa.
• Compounds were profiled against H2122 human lung cancer line and m855 mouse GEM line containing p53/kRas mutations. Compounds were also profiled against diffuse large B-cell lymphoma cell lines OCI-Lyl, OCI-Ly3, OCI-Ly4, OCI-Ly7, S-DHL4, SU- DHL6, SU-DHL7 , HBL1, K422, U2932 and Toledo, and against Burkitt's lymphoma cell lines Raji and Ca46.
• Fig. 1 depicts isobolograms demonstrating the synergy between kinase inhibitors and JQ1. Points below the 1 to 1 line connecting the X and Y axes are 'synergistic', points near the line are 'additive', and points above it are antagonistic.
• Fig. 2 depicts isobolograms representing the synergy between anti-apoptotic agents and JQ1.
• Fig. 3 depicts isobolograms representing the synergy between anti-neoplastic agents and JQ1.
• Fig. 4 depicts isobolograms representing the additive effects between temsirolimus or BEZ235 and JQ1.
• Fig. 5 shows the dose response curves for single agents.
• Table 1 Average CI values for drug combinations

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Molecular Biology (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=53042332

Family Applications (1)

Country Status (9)

Cited By (26)

Families Citing this family (11)

Citations (1)

Family Cites Families (140)

• 2014
  • 2014-11-07 CA CA2929652A patent/CA2929652A1/en not_active Abandoned
  • 2014-11-07 EP EP14860080.2A patent/EP3066101B1/en active Active
  • 2014-11-07 CN CN201480066883.4A patent/CN105849110B/zh not_active Expired - Fee Related
  • 2014-11-07 RU RU2016122654A patent/RU2016122654A/ru not_active Application Discontinuation
  • 2014-11-07 US US15/034,922 patent/US11446309B2/en active Active
  • 2014-11-07 WO PCT/US2014/064549 patent/WO2015070020A2/en not_active Ceased
  • 2014-11-07 JP JP2016528821A patent/JP6637884B2/ja active Active
  • 2014-11-07 KR KR1020167014189A patent/KR20160072261A/ko not_active Ceased
  • 2014-11-07 MX MX2016005980A patent/MX379463B/es unknown
• 2020
  • 2020-07-16 US US16/931,170 patent/US20210100813A1/en not_active Abandoned

Patent Citations (1)

Also Published As

Similar Documents

Legal Events